Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

Shunya Ohmura; Aruna Marchetto; Martin F Orth; Jing Li; Susanne Jabar; Andreas Ranft; Endrit Vinca; Katharina Ceranski; Martha J Carreño-Gonzalez; Laura Romero-Pérez; Fabienne S Wehweck; Julian Musa; Felix Bestvater; Maximilian M L Knott; Tilman L B Hölting; Wolfgang Hartmann; Uta Dirksen; Thomas Kirchner; Florencia Cidre-Aranaz; Thomas G P Grünewald

doi:10.1186/s12943-021-01393-9

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

Mol Cancer. 2021 Jul 27;20(1):97. doi: 10.1186/s12943-021-01393-9.

Authors

Shunya Ohmura^{1

2

3}, Aruna Marchetto³, Martin F Orth³, Jing Li^{1

2}, Susanne Jabar^{4

5}, Andreas Ranft^{4

5}, Endrit Vinca^{1

2}, Katharina Ceranski^{1

2}, Martha J Carreño-Gonzalez^{1

2}, Laura Romero-Pérez^{1

2

3}, Fabienne S Wehweck³, Julian Musa^{1

2

3

6}, Felix Bestvater⁷, Maximilian M L Knott³, Tilman L B Hölting³, Wolfgang Hartmann⁸, Uta Dirksen^{4

5}, Thomas Kirchner^{9

10}, Florencia Cidre-Aranaz^{1

2

3}, Thomas G P Grünewald^{11

12

13

14}

Affiliations

¹ Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
² Division of Translational Pediatric Sarcoma Research (B410), German Cancer Research Center (DKFZ) & Hopp-Children's Cancer Center (KiTZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.
³ Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
⁴ Pediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany.
⁵ German Cancer Consortium (DKTK), partner site Essen, Essen, Germany.
⁶ Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
⁷ Light Microscopy Facility, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
⁸ Division of Translational Pathology, Gerhard-Domagk-Institute for Pathology, University Hospital Münster, Münster, Germany.
⁹ Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
¹⁰ German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
¹¹ Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. t.gruenewald@kitz-heidelberg.de.
¹² Division of Translational Pediatric Sarcoma Research (B410), German Cancer Research Center (DKFZ) & Hopp-Children's Cancer Center (KiTZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany. t.gruenewald@kitz-heidelberg.de.
¹³ Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany. t.gruenewald@kitz-heidelberg.de.
¹⁴ Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany. t.gruenewald@kitz-heidelberg.de.

No abstract available

Keywords: Chemoresistance; Ewing sarcoma; Paediatric oncology; Prognostic biomarker; RRM2; Targeted therapy; Triapine.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Biomarkers, Tumor*
Bone Neoplasms / diagnosis
Bone Neoplasms / etiology*
Bone Neoplasms / therapy
Disease Management
Disease Models, Animal
Disease Susceptibility
Gene Expression Regulation, Neoplastic
Humans
Mice
Molecular Targeted Therapy
Prognosis
Pyridines / pharmacology
Ribonucleoside Diphosphate Reductase / genetics*
Ribonucleoside Diphosphate Reductase / metabolism
Sarcoma, Ewing / diagnosis
Sarcoma, Ewing / etiology*
Sarcoma, Ewing / mortality
Sarcoma, Ewing / therapy
Thiosemicarbazones / pharmacology
Xenograft Model Antitumor Assays

Substances

Biomarkers, Tumor
Pyridines
Thiosemicarbazones
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
ribonucleotide reductase M2
Ribonucleoside Diphosphate Reductase